Spear Pharmaceutical’s Generic to Efudex sold to Mayne Pharmaceuticals

  • Mayne Pharma Group Limited (“Mayne Pharma”) (ASX: MYX) has acquired generic Efudex® (fluorouracil cream 5%) from Spear Pharmaceuticals, Inc. (“Spear”) for up to US$30.0 million

  • Product is immediately EPS accretive with an implied acquisition EBITDA multiple in the low single digits

  • Mayne Pharma will fund the acquisition from cash and undrawn debt

Read the full article here: https://www.maynepharma.com/media/2107/mayne-pharma-acquires-generic-efudex-complementing-us-dermatology-portfolio.pdf

Contact Us

If you have a question on new product development, contact Rachel Phillips at phillips@spearpharma.com.

 

If you would like to contact our sister manufacturing site, Rockledge Pharmaceutical Manufacturing, contact Lorri Renaud at renaud@rpmrx.com 

©2021. Spear Pharmaceuticals. All Rights Reserved. Terms & Conditions of Use.